El mercado de la vacuna contra el virus del papiloma humano (VPH) estaba valorado en 4.273,84 millones de dólares en 2022 y se prevé que alcance los 5.730,50 millones de dólares en 2028; se espera que crezca a una tasa compuesta anual del 5,0 % entre 2022 y 2028.
El virus del papiloma humano (VPH) es un grupo diverso de virus basados en el ADN que infectan las mucosas y membranas de la piel de humanos y diversos animales. Se han caracterizado más de 100 tipos diferentes de VPH. Se espera que la creciente prevalencia de diversos cánceres causados por el VPH impulse el mercado de vacunas contra el virus del papiloma humano (VPH) durante el período previsto. Según los Centros para el Control y la Prevención de Enfermedades (CDC), el VPH es la infección de transmisión sexual más común en Estados Unidos. Más del 60% de los cánceres de pene, el 70% de los cánceres de vulva y vagina y el 90% de los cánceres de ano y cuello uterino son causados por la infección por VPH. Los CDC también afirman que alrededor de 14 millones de personas se infectan por el virus cada año en los EE. UU.
Perspectivas estratégicas
El virus del papiloma humano global ( El mercado de vacunas contra el VPH está segmentado según el tipo, la dosis, la edad, el canal de distribución y la geografía. El mercado, por región, está segmentado en América del Norte, Europa, Asia Pacífico, Medio Oriente y Asia. África y el Sur y el Sur. Centroamérica. El informe ofrece información y un análisis en profundidad del mercado de la vacuna contra el virus del papiloma humano (VPH), haciendo hincapié en varios parámetros, como las tendencias del mercado, los avances tecnológicos y la dinámica del mercado. También incluye el análisis del panorama competitivo de los principales actores del mercado en todo el mundo.
regiones lucrativas para el mercado de vacunas contra el virus del papiloma humano (VPH)
< h3 class="MsoNormal">Perspectiva del mercadoAumento de la prevalencia del VPH asociado Enfermedades
El virus del papiloma humano (VPH) es una infección de transmisión sexual común y puede causar cáncer de cuello uterino, orofaringe y cáncer de vagina, vulva, pene o ano. También provoca diversas enfermedades, como verrugas anogenitales y papilomatosis respiratoria recurrente. Los VPH también se han detectado en liquen escleroso, marcas cutáneas, queratosis seborreicas, quistes epidérmicos, queratosis actínicas y placas psoriásicas. Es probable que una carga significativa de enfermedades asociadas al VPH impulse el crecimiento del mercado.
En las mujeres, el cáncer de cuello uterino es el cuarto cáncer más común. Según la estimación del informe de la Organización Mundial de la Salud (OMS), en 2018, se estima que 570.000 mujeres en todo el mundo padecieron cáncer de cuello uterino y alrededor de 311.000 muertes femeninas se debieron a este cáncer. Además, la Sociedad Estadounidense de Oncología Clínica (ASCO) estimó que solo en Estados Unidos se registrarían alrededor de 14.100 casos de cáncer de cuello uterino invasivo. Además, según el informe 'Carga del cáncer de cuello uterino en la UE-27', en 2020 hubo 30.447 casos nuevos y 13.437 muertes debido al cáncer de cuello uterino en mujeres.
Además, según los Centros de Control y Prevención de Enfermedades (CDC), en 2018, hubo alrededor de 43 millones de infecciones por VPH en los EE. UU. Los CDC también estimaron que alrededor de 19.400 mujeres y 12.100 hombres sufren anualmente de cánceres causados por el VPH. Además, según la Fundación Nacional de Enfermedades Infecciosas (NFID), cada año hay alrededor de 14 millones de nuevos casos de infección por VPH en los EE. UU. Además, según el informe, titulado 'Informe sobre el virus del papiloma humano y enfermedades relacionadas-Europa', en 2020, 8.449 mujeres y 4.327 hombres padecieron cáncer anal en Europa.
Es probable que una incidencia tan alta de infecciones asociadas al VPH en todo el mundo favorezca el crecimiento general del mercado en los próximos años.
Según el tipo, el ser humano El mercado de la vacuna contra el virus del papiloma (VPH) se segmenta en la vacuna contra el VPH 9-valente, la vacuna contra el VPH tetravalente y la vacuna contra el VPH bivalente. En 2022, el segmento de la vacuna tetravalente contra el VPH tendrá la mayor cuota de mercado. Sin embargo, se espera que el mercado del segmento de la vacuna contra el VPH de 9 valencias sea testigo de un rápido crecimiento entre 2022 y 2028. La vacuna tetravalente contra el virus del papiloma humano (VPH) protege contra la infección por los tipos de VPH 6, 11, 16 y 18, que son responsables. para el 70% al 80% de los cánceres de cuello uterino y al menos el 90% de los casos de verrugas genitales. La vacuna reduce el riesgo de verrugas genitales y las lesiones precursoras de los cánceres de cuello uterino, vagina y vulva causados por el virus.
Mercado mundial de vacunas contra el virus del papiloma humano (VPH), por aplicación: 2022 y 2028
Información basada en la dosis
Según la dosis, la vacuna contra el virus del papiloma humano (VPH) El mercado está segmentado en 2 dosis y 3 dosis. En 2022, el segmento de 2 dosis representa una mayor cuota de mercado.
Información basada en la edad
El mercado mundial de vacunas contra el virus del papiloma humano (VPH), según la edad , se segmenta en 9 a 14 años y 15 a 45 años. El segmento de 9 a 14 años tuvo una mayor participación de mercado en 2022 y se prevé que el mismo segmento registre una CAGR más alta durante el período de pronóstico.
Información basada en aplicaciones
En términos de aplicación, el mercado mundial de vacunas contra el virus del papiloma humano (VPH) se segmenta en cánceres atribuibles al VPH y verrugas genitales. El segmento de cánceres atribuibles al VPH tiene una mayor participación de mercado en 2022 y se prevé que el mismo segmento registre una CAGR más alta durante el período de pronóstico.
Información basada en el canal de distribución
Según el canal de distribución, el mercado mundial de vacunas contra el virus del papiloma humano (VPH) se segmenta en consultorios médicos, clínicas de salud comunitarias, centros de salud escolares, departamentos de salud, hospitales y otros. El segmento de hospitales tiene la mayor participación del mercado en 2022, y se prevé que el segmento de centros de salud escolares registre la CAGR más alta del mercado durante el período de pronóstico.
Es probable que la pandemia de COVID-19 tenga consecuencias a largo plazo en el negocio de las vacunas contra el VPH. Muchas clínicas de atención primaria en EE. UU. han seguido funcionando a capacidad reducida para cumplir con las medidas de distanciamiento social y adoptar estrictos protocolos de limpieza. Una reducción de las visitas al consultorio en persona limita las oportunidades para que los proveedores de vacunas hablen y administren las vacunas. Es probable que las barreras en el transporte perjudiquen la vacunación contra el VPH; A las empresas farmacéuticas y biotecnológicas tradicionalmente les resulta difícil comercializar vacunas entre las masas debido a la resistencia recibida de los padres y a la falta de una conciencia generalizada sobre los requisitos de ingreso a la escuela que respaldan otras vacunas para adolescentes. La evidencia disponible indica que la pandemia de COVID-19 ha interrumpido dramáticamente la entrega de vacunas contra el VPH en 2020 y 2021. Los primeros informes de los CDC sugieren que los pedidos y la facturación cayeron >70% en marzo de 2020. Además, un 25-50% La disminución de los pedidos de vacunas contra el VPH continuó en junio de 2020, en contraste con otros pedidos de vacunas para la primera infancia que resurgieron a niveles cercanos a los previos a la pandemia. Aunque la reactivación del mercado de la vacuna contra el VPH está en marcha, los datos disponibles sugieren que una disminución a corto plazo en la cobertura de vacunación contra el VPH será sustancial y que la demanda de la vacuna contra el VPH crecerá en toda América del Norte a largo plazo.
Las empresas suelen adoptar lanzamientos de productos y estrategias de expansión para expandir su presencia en todo el mundo, satisfacer la creciente demanda y ampliar su cartera de productos. Los actores que operan en el mercado mundial de vacunas contra el virus del papiloma humano (VPH) implementan la estrategia de innovación de productos para cambiar la demanda de los clientes en todo el mundo, lo que también les permite mantener su marca a nivel mundial.
- En mayo de 2022, la Administración Nacional de Productos Médicos de China (NMPA) aprobó el esquema de vacuna de dos dosis de GlaxoSmithKline (GSK), Cervarix, en niñas de 9 a 14 años para prevenir el cáncer de cuello uterino. Cervarix es una vacuna bivalente contra el VPH (tipos 16, 18) recombinante, no infecciosa y con adyuvante AS04.
- En mayo de 2022, Serum Institute of India anunció el desarrollo de una vacuna tetravalente contra el VPH que incluye VLP L1. de los serotipos 6,11,16,18, que se espera que brinde una cobertura de ~90% contra el virus del papiloma. La vacuna está actualmente en desarrollo.
- En mayo de 2020, Shanghai Bovax Biotechnology colaboró con Chongoing Bovax Biopharmaceutical para evaluar la inmunogenicidad y seguridad de las vacunas recombinantes contra el VPH 4 y 9 valentes.
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
Human papillomaviruses is a diverse group of DNA-based viruses that infect the mucous and skin membranes of humans and various animals. More than 100 different types of human papillomavirus have been characterized. Increasing prevalence of various cancers caused by human papillomavirus is expected to drive the market during the forecast period. According to the Centers for Disease Control and Prevention (CDC), human papillomavirus is the most common sexually transmitted infection in the U.S. Over 60% of penile cancers, 70% of vulvar and vaginal cancers, and 90% of anal and cervical cancers are caused due to human papillomavirus infection. CDC also states that about 14 million people are newly infected by human papillomavirus every year in the U.S.
Driving factor such as increase in prevalence of HPV associated diseases and initiatives taken by global health organizations are likely to have a positive impact on the growth of the global human papillomavirus (HPV) vaccines market. Whereas factors, such as growing number of HPV awareness programs, are likely to create a growth opportunity on the HPV vaccines market in the near future.
The human papillomavirus vaccine market majorly consists of the players such Merck & Co. In., GSK, Serum Institute of India, Walvax Biotechnologies, Innovax, Vaccitech, Innovio Pharmaceuticals, Chengdu Institute of Biological Products Co., Ltd., Sanofi, R-Pharm, Shanghai Bowei, and Bioleaders amongst others.
The human papillomavirus vaccine market, by type, is bifurcated 9-valent HPV vaccine, quadrivalent HPV vaccine, and bivalent HPV vaccine. In 2022, the quadrivalent HPV vaccine segment held the largest share of the market, by type. However, the 9-valent HPV vaccine segment is expected to witness the fastest growth during 2022 to 2028.
The List Of Companies - HPV Vaccines Market
- Merck & Co. In.
- GSK
- Serum Institute of India
- Walvax Biotechnologies
- Innova
- Vaccitech
- Innovio Pharmaceuticals
- Chengdu Institute of Biological Products Co., Ltd.
- Sanofi
- R-Pharm
- Shanghai Bowei
- Bioleaders
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Related Reports
Jun 2022
Aquatic Veterinary Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Diagnostics and Treatments), Species (Fish, Crustaceans, Mollusca, and Others), Disease Source (Bacteria, Viruses, Parasites, and Others), Route of Administration (Water Medication, Medicated Feed, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Jun 2022
Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis By Treatment (Generic Drugs and Originators), Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Jun 2022
Malaria and Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Treatment [Malaria and Sickle Cell Disease (SCD)], Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Jun 2022
Pharmaceutical Contract Sales Organizations Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Services (Commercial Services and Non-Commercial Services), Modules (Syndicated Modules and Dedicated Modules), Therapeutic Area (Cardiovascular Disorders, Oncology, Metabolic Disorders, Neurology, Orthopedic Diseases, Infectious Diseases, and Others), End User (Biopharmaceutical Companies and Pharmaceutical Companies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Jun 2022
Breast Cancer Therapeutics Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Drug Therapy [Targeted Drug Therapy (Abemaciclib, Ado-Trastuzumab Emtansine, Palbociclib, Trastuzumab, and Other Target Drug Therapies), Hormonal Drug Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, and Selective Estrogen Receptor Downregulators), Chemotherapy, and Immunotherapy/Biological Therapy], Breast Cancer Type (Hormone Receptor, HER2+, and Triple-Negative Breast Cancer), Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, and Online Pharmacies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Jun 2022
Radioactive Tracer Market
Size and Forecast to 2030 - Global Analysis by Tracer Type [Technetium-99m & Tc-97m, Iodine-131, Iron-59, Lutetium-171, Rubidium (Rb-82) Chloride & Ammonia (N-13), Scandium-46, Seaborgium-269, Hassium-269, Gallium Citrate Ga 67, Prostate-Specific Membrane Antigen (PSMA) (Ga-68), FDDNP (F-18) & FDOPA (F-18), Phosphorus-32 & Chromium-51, Thallium-201, F-18 FDG, F-18 FAPI, Ga-68 FAPI, F-18 PSMA, DOTATOC/DOTANOC/DOTATATE (Ga-68), and Others], Test Type (PET, SPECT, and Others), Application (Oncology, Pulmonary, Neurology, Cardiology, and Others) End User (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutes, And Others), and Geography
Jun 2022
Glioma Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Disease (Astrocytoma, Oligoastrocytoma, and Oligodendroglioma), Treatment Type (Surgery, Chemotherapy, Radiation Therapy, and Others), Grade (Low Grade and High Grade), End User (Hospital & Clinics and Ambulatory Surgical Center), and Geography
Jun 2022
Hyperpigmentation Disorder Treatment Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Treatment Type (Cosmeceutical, Light or Laser Therapy, Microdermabrasion, Chemical Peels, Cryotherapy, and Others), Condition (Melasma, Solar Lentigines, Post-Inflammatory Hyperpigmentation, and Others), End User (Hospitals, Dermatology Centers, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)